H.C. Wainwright Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00. The company’s shares opened today at $9.09.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Tsao covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Protagonist Therapeutics, and Argenx Se. According to TipRanks, Tsao has an average return of 9.4% and a 40.80% success rate on recommended stocks.

Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $8.88, a -2.31% downside from current levels. In a report released today, Morgan Stanley also maintained a Hold rating on the stock with a $8.50 price target.

Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million